Cargando…

Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination

IMPORTANCE: The development of a coronavirus disease 2019 (COVID-19) vaccine has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. OBJECTIVE: To examine the factors associated with survey participants’ self-reported likelihood of selecting an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreps, Sarah, Prasad, Sandip, Brownstein, John S., Hswen, Yulin, Garibaldi, Brian T., Zhang, Baobao, Kriner, Douglas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576409/
https://www.ncbi.nlm.nih.gov/pubmed/33079199
http://dx.doi.org/10.1001/jamanetworkopen.2020.25594
_version_ 1783598015576014848
author Kreps, Sarah
Prasad, Sandip
Brownstein, John S.
Hswen, Yulin
Garibaldi, Brian T.
Zhang, Baobao
Kriner, Douglas L.
author_facet Kreps, Sarah
Prasad, Sandip
Brownstein, John S.
Hswen, Yulin
Garibaldi, Brian T.
Zhang, Baobao
Kriner, Douglas L.
author_sort Kreps, Sarah
collection PubMed
description IMPORTANCE: The development of a coronavirus disease 2019 (COVID-19) vaccine has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. OBJECTIVE: To examine the factors associated with survey participants’ self-reported likelihood of selecting and receiving a hypothetical COVID-19 vaccine. DESIGN, SETTING, AND PARTICIPANTS: A survey study of a nonprobability convenience sample of 2000 recruited participants including a choice-based conjoint analysis was conducted to estimate respondents’ probability of choosing a vaccine and willingness to receive vaccination. Participants were asked to evaluate their willingness to receive each hypothetical vaccine individually. The survey presented respondents with 5 choice tasks. In each, participants evaluated 2 hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, vaccine B, or neither vaccine. Vaccine attributes included efficacy, protection duration, major adverse effects, minor adverse effects, US Food and Drug Administration (FDA) approval process, national origin of vaccine, and endorsement. Levels of each attribute for each vaccine were randomly assigned, and attribute order was randomized across participants. Survey data were collected on July 9, 2020. MAIN OUTCOMES AND MEASURES: Average marginal component effect sizes and marginal means were calculated to estimate the relationship between each vaccine attribute level and the probability of the respondent choosing a vaccine and self-reported willingness to receive vaccination. RESULTS: A total of 1971 US adults responded to the survey (median age, 43 [interquartile range, 30-58] years); 999 (51%) were women, 1432 (73%) White, 277 (14%) were Black, and 190 (10%) were Latinx. An increase in efficacy from 50% to 70% was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.06-0.09), and an increase from 50% to 90% was associated with a higher probability of choosing a vaccine (coefficient, 0.16; 95% CI, 0.15-0.18). An increase in protection duration from 1 to 5 years was associated with a higher probability of choosing a vaccine (coefficient, 0.05 95% CI, 0.04-0.07). A decrease in the incidence of major adverse effects from 1 in 10 000 to 1 in 1 000 000 was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.05-0.08). An FDA emergency use authorization was associated with a lower probability of choosing a vaccine (coefficient, −0.03; 95% CI, −0.04 to −0.01) compared with full FDA approval. A vaccine that originated from a non-US country was associated with a lower probability of choosing a vaccine (China: −0.13 [95% CI, −0.15 to −0.11]; UK: −0.04 [95% CI, −0.06 to −0.02]). Endorsements from the US Centers for Disease Control and Prevention (coefficient, 0.09; 95% CI, 0.07-0.11) and the World Health Organization (coefficient, 0.06; 95% CI, 0.04-0.08), compared with an endorsement from President Trump were associated with higher probabilities of choosing a vaccine. Analyses of participants’ willingness to receive each vaccine when assessed individually yielded similar results. An increase in efficacy from 50% to 90% was associated with a 10% higher marginal mean willingness to receive a vaccine (from 0.51 to 0.61). A reduction in the incidence of major side effects was associated with a 4% higher marginal mean willingness to receive a vaccine (from 0.54 to 0.58). A vaccine originating in China was associated with a 10% lower willingness to receive a vaccine vs one developed in the US (from 0.60 to 0.50) Endorsements from the Centers for Disease Control and Prevention and World Health Organization were associated with increases in willingness to receive a vaccine (7% and 6%, respectively) from a baseline endorsement by President Trump (from 0.52 to 0.59 and from 0.52 to 0.58, respectively). CONCLUSIONS AND RELEVANCE: In this survey study of US adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self-reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available.
format Online
Article
Text
id pubmed-7576409
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-75764092020-10-21 Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination Kreps, Sarah Prasad, Sandip Brownstein, John S. Hswen, Yulin Garibaldi, Brian T. Zhang, Baobao Kriner, Douglas L. JAMA Netw Open Original Investigation IMPORTANCE: The development of a coronavirus disease 2019 (COVID-19) vaccine has progressed at unprecedented speed. Widespread public uptake of the vaccine is crucial to stem the pandemic. OBJECTIVE: To examine the factors associated with survey participants’ self-reported likelihood of selecting and receiving a hypothetical COVID-19 vaccine. DESIGN, SETTING, AND PARTICIPANTS: A survey study of a nonprobability convenience sample of 2000 recruited participants including a choice-based conjoint analysis was conducted to estimate respondents’ probability of choosing a vaccine and willingness to receive vaccination. Participants were asked to evaluate their willingness to receive each hypothetical vaccine individually. The survey presented respondents with 5 choice tasks. In each, participants evaluated 2 hypothetical COVID-19 vaccines and were asked whether they would choose vaccine A, vaccine B, or neither vaccine. Vaccine attributes included efficacy, protection duration, major adverse effects, minor adverse effects, US Food and Drug Administration (FDA) approval process, national origin of vaccine, and endorsement. Levels of each attribute for each vaccine were randomly assigned, and attribute order was randomized across participants. Survey data were collected on July 9, 2020. MAIN OUTCOMES AND MEASURES: Average marginal component effect sizes and marginal means were calculated to estimate the relationship between each vaccine attribute level and the probability of the respondent choosing a vaccine and self-reported willingness to receive vaccination. RESULTS: A total of 1971 US adults responded to the survey (median age, 43 [interquartile range, 30-58] years); 999 (51%) were women, 1432 (73%) White, 277 (14%) were Black, and 190 (10%) were Latinx. An increase in efficacy from 50% to 70% was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.06-0.09), and an increase from 50% to 90% was associated with a higher probability of choosing a vaccine (coefficient, 0.16; 95% CI, 0.15-0.18). An increase in protection duration from 1 to 5 years was associated with a higher probability of choosing a vaccine (coefficient, 0.05 95% CI, 0.04-0.07). A decrease in the incidence of major adverse effects from 1 in 10 000 to 1 in 1 000 000 was associated with a higher probability of choosing a vaccine (coefficient, 0.07; 95% CI, 0.05-0.08). An FDA emergency use authorization was associated with a lower probability of choosing a vaccine (coefficient, −0.03; 95% CI, −0.04 to −0.01) compared with full FDA approval. A vaccine that originated from a non-US country was associated with a lower probability of choosing a vaccine (China: −0.13 [95% CI, −0.15 to −0.11]; UK: −0.04 [95% CI, −0.06 to −0.02]). Endorsements from the US Centers for Disease Control and Prevention (coefficient, 0.09; 95% CI, 0.07-0.11) and the World Health Organization (coefficient, 0.06; 95% CI, 0.04-0.08), compared with an endorsement from President Trump were associated with higher probabilities of choosing a vaccine. Analyses of participants’ willingness to receive each vaccine when assessed individually yielded similar results. An increase in efficacy from 50% to 90% was associated with a 10% higher marginal mean willingness to receive a vaccine (from 0.51 to 0.61). A reduction in the incidence of major side effects was associated with a 4% higher marginal mean willingness to receive a vaccine (from 0.54 to 0.58). A vaccine originating in China was associated with a 10% lower willingness to receive a vaccine vs one developed in the US (from 0.60 to 0.50) Endorsements from the Centers for Disease Control and Prevention and World Health Organization were associated with increases in willingness to receive a vaccine (7% and 6%, respectively) from a baseline endorsement by President Trump (from 0.52 to 0.59 and from 0.52 to 0.58, respectively). CONCLUSIONS AND RELEVANCE: In this survey study of US adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self-reported willingness to receive vaccination. These results may help inform public health campaigns to address vaccine hesitancy when a COVID-19 vaccine becomes available. American Medical Association 2020-10-20 /pmc/articles/PMC7576409/ /pubmed/33079199 http://dx.doi.org/10.1001/jamanetworkopen.2020.25594 Text en Copyright 2020 Kreps S et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Kreps, Sarah
Prasad, Sandip
Brownstein, John S.
Hswen, Yulin
Garibaldi, Brian T.
Zhang, Baobao
Kriner, Douglas L.
Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title_full Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title_fullStr Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title_full_unstemmed Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title_short Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination
title_sort factors associated with us adults’ likelihood of accepting covid-19 vaccination
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576409/
https://www.ncbi.nlm.nih.gov/pubmed/33079199
http://dx.doi.org/10.1001/jamanetworkopen.2020.25594
work_keys_str_mv AT krepssarah factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT prasadsandip factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT brownsteinjohns factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT hswenyulin factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT garibaldibriant factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT zhangbaobao factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination
AT krinerdouglasl factorsassociatedwithusadultslikelihoodofacceptingcovid19vaccination